MedTrace Logo

Ablation of Hepatocellular Carcinoma: a Nationwide Study

NCT05498779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 490

Last updated 2023-11-28

No results posted yet for this study

Summary

Background Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Chronic infection with hepatitis C virus (HCV) is a significant risk factor and may be associated with inferior outcome. According to the Danish national guidelines, ablation should be offered patients with early HCC (tumor \< 3 cm) in a cirrhotic liver, who are not transplant candidates. However, the effect of size of the HCC tumor and Hepatitis C virus (HCV) as etiology are insufficiently investigated.

Purposes

1. Investigate association between HCC tumor size and survival and recurrence after ablation.
2. Investigate survival and recurrence after ablation in patients with HCV-related HCC compared with HCC due to other etiologies.

Methods This study is based on data from the Danish Liver and Bile Duct Cancer Database (DLGCD) and the Danish Database for Hepatitis B and C (DANHEP) and the laboratory database (DANVIR), which collectively include information on patient characteristics, tumor characteristic, laboratory results, and information regarding ablation, HCV status, and antiviral treatment, respectively.

Perspectives Ablation has been widely used for decades, but studies investigating the effect of ablation for HCC in patients with HCV and size of HCC are lacking. This study will contribute considerably to the level of evidence and may impact both Danish and international guidelines for HCC treatment.

Conditions

Interventions

PROCEDURE

Ablation therapy

Radiofrequency or microwave ablation

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Hans-Christian Pommergaard, MD, ph.d. · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05498779 on ClinicalTrials.gov